transparent gif


Ej inloggad.

Göteborgs universitets publikationer

Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy.

Författare och institution:
Changlian Zhu (-); Wenqing Kang (-); Falin Xu (-); Xiuyong Cheng (-); Zhan Zhang (-); Liting Jia (-); Ling Ji (-); Xiaoyan Guo (-); Hong Xiong (-); George Simbruner (-); Klas Blomgren (Institutionen för neurovetenskap och fysiologi, sektionen för klinisk neurovetenskap och rehabilitering & Institutionen för kliniska vetenskaper, sektionen för kvinnors och barns hälsa); Xiaoyang Wang (-)
Publicerad i:
Pediatrics, 124 ( 2 ) s. e218-26
Artikel, refereegranskad vetenskaplig
Sammanfattning (abstract):
OBJECTIVE: The purpose of this study was to evaluate the efficacy and safety of erythropoietin in neonatal hypoxic-ischemic encephalopathy (HIE), by using a randomized, prospective study design. METHODS: A total of 167 term infants with moderate/severe HIE were assigned randomly to receive either erythropoietin (N = 83) or conventional treatment (N = 84). Recombinant human erythropoietin, at either 300 U/kg (N = 52) or 500 U/kg (N = 31), was administered every other day for 2 weeks, starting <48 hours after birth. The primary outcome was death or disability. Neurodevelopmental outcomes were assessed at 18 months of age. RESULTS: Complete outcome data were available for 153 infants. Nine patients dropped out during treatment, and 5 patients were lost to follow-up monitoring. Death or moderate/severe disability occurred for 35 (43.8%) of 80 infants in the control group and 18 (24.6%) of 73 infants in the erythropoietin group (P = .017) at 18 months. The primary outcomes were not different between the 2 erythropoietin doses. Subgroup analyses indicated that erythropoietin improved long-term outcomes only for infants with moderate HIE (P = .001) and not those with severe HIE (P = .227). No negative hematopoietic side effects were observed. CONCLUSION: Repeated, low-dose, recombinant human erythropoietin treatment reduced the risk of disability for infants with moderate HIE, without apparent side effects.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
Asphyxia Neonatorum, diagnosis, drug therapy, Brain Damage, Chronic, diagnosis, prevention & control, China, Developmental Disabilities, diagnosis, prevention & control, Disability Evaluation, Dose-Response Relationship, Drug, Drug Administration Schedule, Erythropoietin, Recombinant, administration & dosage, adverse effects, Female, Follow-Up Studies, Humans, Hypoxia-Ischemia, Brain, diagnosis, drug therapy, Infant, Infant, Newborn, Infusions, Intravenous, Injections, Subcutaneous, Intensive Care Units, Neonatal, Male, Neurologic Examination, drug effects, Prospective Studies, Psychomotor Disorders, diagnosis, prevention & control
Postens nummer:
Posten skapad:
2009-08-25 15:14
Posten ändrad:
2011-01-20 10:00

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007